Clinical Trials
44 trialsNCT02364713 2025-12-11
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
Phase 2 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02569957 2025-05-04
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT00170625 2024-11-12
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
Phase 1/2 Completed
NCT02649673 2023-12-05
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
SCRI Development Innovations, LLC
Phase 1 Terminated
NCT00657878 2023-11-13
MITO-8
National Cancer Institute, Naples
Phase 3 Unknown
NCT00317772 2022-02-07
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04679064 2021-08-27
NItCHE-MITO33
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Unknown
NCT02903004 2021-08-25
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Completed
NCT00652691 2019-04-08
Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
Mayo Clinic
Phase 1 Completed
NCT03367182 2019-01-11
REBECA
Yonsei University
Completed
NCT00720096 2018-01-02
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT00287859 2017-11-29
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00437307 2016-09-22
HECTOR
North Eastern German Society of Gynaecological Oncology
Phase 3 Completed
NCT01003938 2016-06-30
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
NYU Langone Health
Phase 2 Terminated
NCT00045175 2016-06-23
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
University Health Network, Toronto
Phase 1 Completed
NCT00526799 2016-03-03
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT00006454 2015-12-23
Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer
AGO Study Group
Phase 3 Completed
NCT00072267 2015-07-23
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
University Health Network, Toronto
Phase 2 Completed
NCT01690598 2015-06-10
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
Vejle Hospital
Phase 1/2 Completed
NCT00343044 2015-05-15
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Benaroya Research Institute
Phase 2 Completed
NCT00550784 2014-10-07
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
City of Hope Medical Center
Phase 1 Completed
NCT00170677 2014-05-14
Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
Phase 2 Completed
NCT00436644 2014-04-16
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
Mayo Clinic
Phase 2 Completed
NCT00523432 2013-09-05
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
University of Chicago
Phase 1 Completed
NCT00002515 2013-06-24
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003944 2013-04-17
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00842452 2013-04-05
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery
Case Comprehensive Cancer Center
Phase 1 Completed
NCT01177501 2012-11-19
ITOV04
Assistance Publique - Hôpitaux de Paris
Phase 1 Terminated
NCT00005051 2012-11-09
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
NYU Langone Health
Phase 2 Completed
NCT00005612 2012-09-26
ETC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00231855 2012-04-24
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
Montefiore Medical Center
Phase 2 Completed
NCT00250094 2011-09-07
Clinical Benefit of Topoisomerase Downregulation
New Mexico Cancer Research Alliance
Phase 1 Completed
NCT00429559 2011-07-22
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Hellenic Oncology Research Group
Phase 1/2 Completed
NCT00193297 2011-05-03
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00006391 2011-04-05
Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NYU Langone Health
Phase 1 Completed
NCT00003297 2011-03-24
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer
Georgetown University
Phase 1/2 Completed
NCT00189566 2011-02-25
Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT00217555 2010-09-21
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00315861 2009-01-23
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00194935 2006-09-13
Weekly Topotecan Therapy in Patients With Ovarian Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT00102375 2006-08-04
Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer
AGO Study Group
Phase 3 Completed
NCT00312988 2006-04-11
Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy
North Eastern German Society of Gynaecological Oncology
Phase 3 Completed